Goldman, Sachs & Co., Credit Suisse Securities (USA) LLC, J.P. Morgan Securities Inc. and Morgan Stanley will act as joint book-running managers for the proposed offering.
A copy of the prospectus relating to these securities may be obtained, when available, from: Goldman, Sachs & Co., Attn: Prospectus Department, 85 Broad Street, New York, NY 10004 via fax at (212) 902-9316 or email at prospectus-ny@ny.email.gs.com.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any State in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State.
The Company
Warner Chilcott is a leading specialty pharmaceutical company focused on marketing, selling, developing and manufacturing branded prescription products in women's healthcare and dermatology in the United States.
Source: Warner Chilcott Holdings Company, Limited
